(e7)
Open as .pdf
See at PubMed | The neurological safety of covid-19 vaccines
Pottegård A, Klungel OH.
BMJ. 2022 Mar 16;376:o522.
|
(e6)
Open as .pdf
See at PubMed | Translational pharmacology: Closing the mechanistic gap
Pottegård A, Stage TB.
Basic Clin Pharmacol Toxicol. 2022 Jan;130 Suppl 1:3-4
|
(e5)
Open as .pdf
See at PubMed | Strengthening international surveillance of vaccine safety
Klungel OH, Pottegård A.
BMJ. 2021 Aug 26;374:n1994.
|
(e4)
Open as .pdf
See at PubMed | Considerations regarding choice of primary outcome in clinical trials in deprescribing
Lundby C, Pottegård A.
Br J Clin Pharmacol. 2022 Jul;88(7):3032-3034.
|
(e3)
Open as .pdf
See at PubMed | The International Society for Pharmacoepidemiology’s Comments on the Core Recommendations in the Summary of the Heads of Medicines Agencies (HMA) - EMA Joint Big Data Task Force
Pottegård A, Klungel OH, Winterstein A, Huybrechts K, Hallas J, Schneeweiss S, Evans S, Bate A, Pont L, Trifirò G, Smith M, Bourke A.
Pharmacoepidemiol Drug Saf. 2019 Dec;28(12):1640-1641
|
(e2)
Open as .pdf
See at PubMed | Identifying signals of interest when screening for drug-outcome associations in healthcare data
Pottegård A, Hallas J, Wang SV, Gagne JJ.
Br J Clin Pharmacol. 2018 Sep;84(9):1865-1867
|
(e1)
Open as .pdf
See at PubMed | Reuse of data sources to evaluate drug safety signals: When is it appropriate?
Wang SV, Kulldorff M, Glynn RJ, Gagne JJ, Pottegård A, Rothman KJ, Schneeweiss S, Walker AM.
Pharmacoepidemiol Drug Saf. 2018 Jun;27(6):567-569
|
|
|
